FDA Questions Data Supporting ReGen's Menaflex Ahead Of 510(k) Re-Review
This article was originally published in The Gray Sheet
Executive Summary
FDA raised concerns about the preclinical and clinical data used to support 510(k) clearance of ReGen Biologic's Menaflex knee repair device ahead of an unprecedented March 23 advisory panel to reconsider FDA's original clearance decision